Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 171439, 11 pages
http://dx.doi.org/10.1155/2014/171439
Research Article

Using Targeted Virotherapy to Treat a Resistant Ewing Sarcoma Model: From the Bedside to the Bench and Back

1University of Ottawa, Division of Orthopaedic Surgery, Ottawa Hospital General Campus, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6
2Department of Orthopaedic Surgery, Queensway-Carleton Hospital, 3045 Baseline Road, Ottawa, ON, Canada K2H 8P4
3University of Ottawa, Ottawa Regional Cancer Center Research Laboratories, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6

Received 11 August 2013; Accepted 27 October 2013; Published 12 January 2014

Academic Editors: V. C. Cheng and Y. Kanegae

Copyright © 2014 Hesham Abdelbary et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. P. Ginsberg, P. Goodman, W. Leisenring et al., “Long-term survivors of childhood ewing sarcoma: report from the childhood cancer survivor study,” Journal of the National Cancer Institute, vol. 102, no. 16, pp. 1272–1283, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Gangwal, D. Close, and C. A. Enriquez, “Emergent properties of EWS/FLI regulation via GGAA microsatellites in ewing’s sarcoma,” Genes Cancer, vol. 1, no. 2, pp. 177–187, 2010. View at Google Scholar
  3. R. D. Riley, S. A. Burchill, K. R. Abrams et al., “A systematic review and evaluation of the use of tumour markers in paediatric oncology: ewing's sarcoma and neuroblastoma,” Health Technology Assessment, vol. 7, no. 5, 2003. View at Google Scholar · View at Scopus
  4. T. L.-A. Nguyên, H. Abdelbary, M. Arguello et al., “Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 39, pp. 14981–14986, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. K. A. Parato, D. Senger, P. A. J. Forsyth, and J. C. Bell, “Recent progress in the battle between oncolytic viruses and tumours,” Nature Reviews Cancer, vol. 5, no. 12, pp. 965–976, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. T. O'Hare, C. A. Eide, and M. W. Deininger, “New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check,” Expert Opinion on Investigational Drugs, vol. 17, no. 6, pp. 865–878, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. D. F. Stojdl, B. D. Lichty, B. R. TenOever et al., “VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents,” Cancer Cell, vol. 4, no. 4, pp. 263–275, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. C. J. Breitbach, J. M. Paterson, C. G. Lemay et al., “Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow,” Molecular Therapy, vol. 15, no. 9, pp. 1686–1693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. T.-C. Liu, E. Galanis, and D. Kirn, “Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress,” Nature Clinical Practice Oncology, vol. 4, no. 2, pp. 101–117, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. C. L. Morton, P. J. Houghton, E. A. Kolb et al., “Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program,” Pediatric Blood and Cancer, vol. 55, no. 2, pp. 295–303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Takakuwa, F. Goshima, N. Nozawa et al., “Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice,” Archives of Virology, vol. 148, no. 4, pp. 813–825, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. C. Paglino and A. N. van den Pol, “Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways,” Journal of Virology, vol. 85, no. 18, pp. 9346–9358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. D. F. Stojdl, B. Lichty, S. Knowles et al., “Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus,” Nature Medicine, vol. 6, no. 7, pp. 821–825, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. C. W. Brown, K. B. Stephenson, S. Hanson et al., “The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis,” Journal of Virology, vol. 83, no. 2, pp. 552–561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Le Boeuf, J.-S. Diallo, J. A. McCart et al., “Synergistic interaction between oncolytic viruses augments tumor killing,” Molecular Therapy, vol. 18, no. 5, pp. 888–895, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J.-S. Diallo, D. Roy, H. Abdelbary, N. de Silva, and J. C. Bell, “Ex vivo infection of live tissue with oncolytic viruses,” Journal of Visualized Experiments, no. 52, Article ID e2854, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Maire, C. W. Brown, J. Bayani et al., “Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversion-insertion mechanism of EWS-ERG fusion gene formation: a case analysis and literature review,” Cancer Genetics and Cytogenetics, vol. 181, no. 2, pp. 81–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. J. P. Ginsberg, E. De Alava, M. Ladanyi et al., “EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1809–1814, 1999. View at Google Scholar · View at Scopus
  19. E. De Alava, A. Panizo, C. R. Antonescu et al., “Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma,” American Journal of Pathology, vol. 156, no. 3, pp. 849–855, 2000. View at Google Scholar · View at Scopus
  20. K. Kurozumi, J. Hardcastle, R. Thakur et al., “Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy,” Journal of the National Cancer Institute, vol. 99, no. 23, pp. 1768–1781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Li, A. Dutuor, X. Fu, and X. Zhang, “Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model,” Journal of Gene Medicine, vol. 9, no. 3, pp. 161–169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C. G. Lemay, J. L. Rintoul, A. Kus et al., “Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine,” Molecular Therapy, vol. 20, no. 9, pp. 1791–1799, 2012. View at Google Scholar